Drug intelligence / Profile preview

KFP-H015

Development stage: Preclinical
Lead developer: Nanjing Carephar Pharmaceutical
Modality: Small Molecules

Overview

KFP-H015 is an investigational small molecule antiviral agent being developed by Nanjing Carephar Pharmaceutical. As of the latest pipeline information, the drug is in the IND-enabling (Investigational New Drug) stage, preparing for clinical entry. While it is categorized as an anti-virus therapy, the specific viral target (such as a viral protease, polymerase, or entry inhibitor) and the specific pathogen it targets (e.g., SARS-CoV-2, Hepatitis, or Influenza) have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on KFP-H015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFP-H015.

Explore the full profile